Join Free For Buyer|Sign In
Professional Online Trade Platform for API, Preparation and Pharmaceutical Machinery and Equipment_EN-CPhI.cn

You are here:  Home >>  News

Editors' Picks
  • The Big Era for Investment of “RNAi Drugs” from the Perspective of Two Newly Approved Drugs by FDA
    FDA approved the Exondys 51 (eteplirsen) of Sarepta Therapeutics on September 19, 2016 for treating exon 51 skipping Duchenne muscular dystrophy (DMD).
  • ICH flooded the screen, China’s joining of ICH not officially recognized yet
    It has been reported early in the morning of June 2 that CFDA was voted to formally become a full member of ICH at the venue in Montreal.

Market News

Teva, Xenon Announce Phase II Study of Topical TV-45070 Did Not Meet Primary Endpoint
Teva Pharmaceutical and Xenon Pharmaceuticals announce top-line results in a Phase II study of topical TV-45070 in patients with post-herpetic neu...
By:americanpharmaceuticalreview
2017.06.28

Policy & Regulation

Rise in product recalls prompts FDA to warn of possible BCC contamination
The US Food and Drug Administration (FDA) has advised manufacturers of non-sterile, water-based drug products that there have been recent product r...
By:europeanpharmaceuticalreview
2017.06.29

Company News

Strategic alliance between Alma Bio Therapeutics and Delphi Genetics on Plasmid DNA drugs
Partnership will advance development of drugs aimed at treating underlying cause of uncontrolled inflammation in autoimmune diseases
By:biospectrumasia
2017.06.29
CPhI Online Trade Platform: Worldwide|English|中国站
Customer Service:  86-400 610 1188 (9: 00-18: 00, Mon-Fri)
About Us| Contact Us| Terms of Services| Privacy Policy| Intellectual Property Statement| Links | Site Map
Copyright 2006-20 Shanghai UBM Sinoexpo International Exhibition Co Ltd (All Rights Reserved). ICP 05034851-53